Clinical Trials Logo

Intermediate Uveitis clinical trials

View clinical trials related to Intermediate Uveitis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT01280669 Withdrawn - Uveitis Clinical Trials

Intravitreal Sirolimus as Therapeutic Approach to Uveitis

SAVE-2
Start date: September 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out about the safety and effectiveness of two different doses the study drug, sirolimus, administered intravitreally in patients with uveitis. The potential effectiveness of sirolimus can be utilized to control inflammation in uveitis and yet avoid the potential complications that are usually associated with the systemic use of the drug and other immunomodulatory therapies. In this study, the investigators will administer sirolimus inside the eye (intravitreally) in one of two doses (440mcg/mcL or 880mcg/mcL). Local administration of sirolimus to the eye is not expected to have effects on the rest of the body. Therefore, it may offer a safer way than the current methods used to control the inflammation caused by non-infectious uveitis.